ATRA · Atara Biotherapeutics Inc

-

Please sign in to comment on ATRA

1 Comment

Admin

4 years ago

Atara Biotherapeutics, Inc is currently in a long term downtrend where the price is trading 13.8% below its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

Atara Biotherapeutics, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.

Its net income has dropped by 3.6% to $-81M since the same quarter in the previous year.

Finally, its free cash flow grew by 92.3% to $-5M since the same quarter in the previous year.

Based on the above factors, Atara Biotherapeutics, Inc gets an overall score of 2/5.

Industry	Biotechnology
Sector	Healthcare
Exchange	NASDAQ
CurrencyCode	USD
ISIN	US0465131078

Beta	0.32
Market Cap	40M
PE Ratio	None
Target Price	14
Dividend Yield	None

ABOUT

Atara Biotherapeutics Inc

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

ATRA · Atara Biotherapeutics Inc

-

Atara Biotherapeutics Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Atara Biotherapeutics Inc using a moving average strategy